New to the Huntington's Disease Lighthouse?
 Welcome to the HDlighthouse!
 Getting started.
 
Home \ Research \ Drugs and Supplements \ Updates
Mithramycin extends suvival in HD mice in the best results seen to date for any compound.

HD Lighthouse Contributing Editor's Comment: Doctors Robert Ferrante and Rajiz Ratan, with multiple collaborators, are lead authors of the recent article which details neuroprotective benefits of the drug mithramycin as found in “Chemotherapy for the Brain” (November 17 Journal of Neuroscience). Their elegant long story briefly summarized: Mithramycin extended survival of the HD R6/2 mouse longer than any other agent so far described. Likewise it improved motor performance more than any other agent. And most importantly, brain changes usually present in the R6/2 mouse were so much improved they were “essentially absent”. Though the authors use “comparatively large effect” as their careful language, these combined results are much better than for any other agent so far studied.

And, though mithramycin is not an easy drug to work with, it is already FDA approved. And accordingly the authors make the argument that mithramycin should be among the top priorities for testing in patients.
--LaVonne Veatch Goodman, M.D.
Posted to the HDL: 25 Nov 2004



Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease

Huntington's disease (HD) is a fully penetrant autosomal-dominant inherited neurological disorder caused by expanded CAG repeats in the Huntingtin gene. Transcriptional dysfunction, excitotoxicity, and oxidative stress have all been proposed to play important roles in the pathogenesis of HD. This study was designed to explore the therapeutic potential of mithramycin, a clinically approved guanosine-cytosine-rich DNA binding antitumor antibiotic. Pharmacological treatment of a transgenic mouse model of HD (R6/2) with mithramycin extended survival by 29.1%, greater than any single agent reported to date. Increased survival was accompanied by improved motor performance and markedly delayed neuropathological sequelae. To identify the functional mechanism for the salubrious effects of mithramycin, we examined transcriptional dysfunction in R6/2 mice. Consistent with transcriptional repression playing a role in the pathogenesis of HD, we found increased methylation of lysine 9 in histone H3, a well established mechanism of gene silencing. Mithramycin treatment prevented the increase in H3 methylation observed in R6/2 mice, suggesting that the enhanced survival and neuroprotection might be attributable to the alleviation of repressed gene expression vital to neuronal function and survival. Because it is Food and Drug Administration-approved, mithramycin is a promising drug for the treatment of HD.
# # #

Source: J Neurosci. 2004 Nov 17;24(46):10335-10342

print this
printer friendly
version

 

Read the HDAC/HDLighthouse Forum. Post your comments
   
Related Topics
Research focusing on the formation of aggregates caused by HD
 
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
 
Research related HD and it's general affect on the brain
 
Learn more about the clinical trial process, trials that have been conducted and those that are underway.
 
Research focusing on gene therapy.
 
Research focusing on gene transcription.
 
General research related to HD
 
Research studying the genetics of Huntington's Disease
 
Research studying the Immune System and it's effect on the progression of HD
 
Research studying the brain tissue and research related to stem cells
 
Recent Updates
24 Apr 2009
An ampakine upregulates BDNF
An ampakine, a modulator of glutamate receptors, reduced memory and learning problems in HD mice.
 
8 Apr 2009
Amarin files new drug application for AMR 101 in Europe
Ethyl-EPA remains in the drug development pipeline.
 
3 Feb 2009
The ACR-16 trial is enrolling participants
An interview with lead investigator Dr. Karl Kieburtz.
 
31 Jan 2009
Surprising Finding Points to Possible Treatment for Huntington Disease
Drugs that increase the activity of PPAR-delta are added to the pipeline of potential treatments.
 
1 Jan 2009
Long term tetrabenazine use
In an Italian study, TBZ improved chorea for most patients; over time the magnitude of the benefit declined somewhat.
 
15 Dec 2008
Ethyl-EPA research report published
Ethyl-EPA is still in the research pipeline.
 
13 Oct 2008
Ethyl-EPA reduces cerebral atrophy in HD patients
Treatment with ethyl-EPA is associated with significant reduction in brain atrophy, particularly in the caudate and thalamus.
 
10 Oct 2008
A new HDAC inhibitor
Scripts Research Institute has developed a new HDAC inhibitor that partially restores normal gene transcription and improves movement and brain volume in the HD mice.
 
6 Oct 2008
Cytochrome c release as a therapeutic target
Methazolamide delays disease onset and significantly prolongs survival in the R6/2 mouse model of HD.
 
21 Sep 2008
Why did CEP-1347 fail in the Parkinson′s trial?
The possible reasons for the failure of CEP-1347 as a PD treatments are reviewed.
 

All Updates for Drugs and Supplements
Disclaimer & Privacy Policy | Welcome | Site Feedback Marsha@HDLighthouse.org